According to the research report, the global drug discovery outsourcing market size is expected to touch USD 6.55 Billion by 2030, from USD 3.86 Billion in 2022, growing with a significant CAGR of 6.8% from 2022 to 2030.
The drug discovery outsourcing report
offers a comprehensive study of the current state expected at the major
drivers, market strategies, and key vendors’ growth. The report presents
energetic visions to conclude and study the market size, market hopes, and
competitive surroundings. The research also focuses on the important
achievements of the market, research & development, and regional growth of
the leading competitors operating in the market. The current trends of the
global drug discovery outsourcing in conjunction with the geographical
landscape of this vertical have also been included in this report.
The report offers intricate dynamics about
different aspects of the global drug discovery outsourcing market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global drug discovery outsourcing during the forecast
period. It also includes a key indicator assessment that highlights growth
prospects of this market and estimates statistics related to growth of the
market in terms of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1549
| Report Coverage | Details |
| Market Size | US$ 6.55 Billion by 2030 |
| Growth Rate | CAGR of 6.8% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Workflow, Therapeutic Area, Drug Type, Region |
This study covers a detailed segmentation
of the global drug discovery outsourcing market, along with key information and
a competition outlook. The report mentions company profiles of players that are
currently dominating the global drug discovery outsourcing market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Albany Molecular Research Inc.
- EVOTEC
- Laboratory Corporation of America Holdings
- GenScript
- Pharmaceutical Product Development, LLC.
- Charles River
- WuXiAppTec
- Merck & Co., Inc.
- Thermo Fisher Scientific Inc.
- Dalton Pharma Services
- Oncodesign
- Jubilant Biosys
- DiscoverX Corporation
- QIAGEN
Market Segmentation
- Target Identification & Screening
- Lead Identification & Candidate Optimization
- Target Validation & Functional Informatics
- Preclinical Development
- Others
By Therapeutic Area
- Oncology
- Cardiovascular
- Gastrointestinal
- Neurology
- Respiratory
- Others
By Drug Type
- Biologics
- Small Molecules
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global drug discovery outsourcing report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global drug discovery outsourcing market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug Discovery Outsourcing Market
5.1. COVID-19 Landscape: Drug Discovery Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug Discovery Outsourcing Market, By Workflow
8.1. Drug Discovery Outsourcing Market, by Workflow Type, 2022-2030
8.1.1. Target Identification & Screening
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Lead Identification & Candidate Optimization
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Target Validation & Functional Informatics
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Preclinical Development
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug Discovery Outsourcing Market, By Therapeutic Area
9.1. Drug Discovery Outsourcing Market, by Therapeutic Area, 2022-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cardiovascular
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Gastrointestinal
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Respiratory
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug Discovery Outsourcing Market, By Drug Type
10.1. Drug Discovery Outsourcing Market, by Drug Type, 2022-2030
10.1.1. Biologics
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Small Molecules
10.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
Chapter 12. Company Profiles
12.1. Albany Molecular Research Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. EVOTEC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Laboratory Corporation of America Holdings
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GenScript
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pharmaceutical Product Development, LLC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Charles River
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WuXiAppTec
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Thermo Fisher Scientific Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Dalton Pharma Services
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Oncodesign
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Jubilant Biosys
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. DiscoverX Corporation
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments